Dutch biotech spun off from Leiden developing NNMT inhibitors for obesity and metabolic syndrome.
| Date | Round | Amount |
|---|---|---|
| Sep 2025 | Funding round Cantoni Therapeutics closed a financing round (undisclosed amount) led by Libertatis Ergo Holding with BOM and BSF, plus a Novo Nordisk grant, to bring its NNMT inhibitor to IND stage. | — |
Tap an investor to see what else they have backed.
Data is community-curated and may be incomplete.